UNSPSC 51392201: Alinidine

This classification denotes an alpha-adrenergic agonist with the molecular formula C12H13Cl2N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E7IDJ8DS1D, chemically known as 2-(n-allyl-n-(2,6-dichlorophenyl)amino)-2-imidazoline but generally known as alinidine, which bears US NIH Compound Identifier 36354. Alinidine most often comes in base and hydrobromide forms. European Medicines Agency schedules Alinidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05330MIG.

UNSPSC 51392201 Alinidine is a Commodity code that does not align with recent state and local procurement activity in the available opportunities block. The two most recent opportunities tagged under this code—a Seminole County, Florida naloxone and safe drug deactivation systems procurement (IFB60459723LAS) and a Texas Health and Human Services Commission direct-to-manufacturer prescription program RFI (HHS0017013)—concern naloxone distribution and pharmaceutical contracting models, not alinidine, a cardiac drug with narrow clinical use. The mismatch between the code's nominal scope and the actual work being solicited suggests either miscoding in the state and local systems or that alinidine sees minimal procurement activity among jurisdictions tracked in this dataset. State and local health agencies, including county community health departments and state HHS commissions, appear to be the primary issuing bodies for pharmaceutical-related procurements when activity does occur, though the opportunities shown diverge substantially from the code's stated commodity.

The geographic spread of recent activity is limited to Florida and Texas, with no additional jurisdictions represented in the current opportunities block. Seminole County's naloxone solicitation, posted June 30, 2026, with a response deadline of July 26, 2023 (a date discrepancy in the source), and the Texas HHS RFI, posted April 3, 2026, also due April 3, 2026, are the only traceable recent signals. The code shows little relevant recent activity and may warrant review against the actual commodity codes under which these health agencies procure pharmaceuticals and drug-management systems.